Search Results
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Search for other papers by Massimiliano Succi in
Google Scholar
PubMed
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Europe, the multikinase inhibitors sorafenib, lenvatinib (LEN) and cabozantinib have been approved for RAI-R DTC, vandetanib (VAN) and cabozantinib for MTC, and the gene-targeted selpercatinib (SELP) and larotrectinib for cancers harbouring rearranged